Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LITS with free AI briefings, catalyst countdowns, and dilution alerts.

LITS · Lite Strategy, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$4.3M Cash on Hand
7.7mo Cash Runway
Follow LITS by email Get an email when LITS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LITS, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

LITS holds $4.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.7M/quarter from operations, an estimated runway of 7.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LITS files for a raise →

👥 Who Owns LITS

Insiders 13.9% Institutions (40 holders) 17.9% Public and other holders 68.2%
HolderTypeShares% of sharesAs of
Alexander Schornstein
10% owner
Insider 3,674,862 12.30% 2025-12-18
Charles Benjamin Lee
Director · +10,000 options
Insider 292,397 0.98% 2025-07-22
James P Flynn
Director · +201,700 options
Insider 125,000 0.42% 2026-06-24
Steven D Wood
Director · +40,000 options
Insider 72,092 0.24% 2025-07-15
Nicholas Glover
Director · +175,000 options
Insider 2,000 0.01% 2025-07-22
Frederick W Driscoll
Director · +175,000 options
Insider 1,875 0.01% 2025-07-15
Thomas C Reynolds
Director · +20,000 options
Insider 500 0.00% 2025-07-15

Share count 29,884,653 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full LITS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LITS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.